Weekly Journal Scan: VESALIUS-CV extends PCSK9 inhibition to the prevention of first major cardiovascular events
A recent editorial in the European Heart Journal highlights the pivotal VESALIUS-CV trial, which extends the clinical application of PCSK9 inhibitors. The trial evaluated the monoclonal antibody evolocumab in patients without a prior history of myocardial infarction or stroke, demonstrating its efficacy in preventing first major adverse cardiovascular events. This represents a significant shift from secondary to primary prevention in cardiovascular risk management, broadening the potential patient population for this lipid-lowering therapy.
Why it might matter to you: For hematologists and specialists managing coagulation and thrombosis, this expansion of PCSK9 inhibitors into primary prevention has direct implications for patient stratification and long-term anticoagulation strategies. It underscores the evolving intersection between lipidology, vascular health, hematopoiesis, and thrombotic risk assessment. This development may influence collaborative care pathways and inform discussions on comprehensive cardiovascular risk reduction beyond traditional anticoagulation.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
